PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells by Marfe, Gabriella et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Cancer
Open Access Research article
PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) 
induce apoptosis in K562 cells
Gabriella Marfe*1, Carla Di Stefano1, Romano Silvestri2, 
Elisabetta Abruzzese3, Gianfranco Catalano3, Livia Di Renzo6, 
Giuseppe Filomeni4, Ezio Giorda5, Giuseppe La Regina2, 
Emanuela Morgante6,7, Maria Rosa Ciriolo4,7, Matteo Antonio Russo6,7, 
Sergio Amadori3 and Paola Sinibaldi-Salimei1
Address: 1Department of Experimental Medicine and Biochemical Sciences, University of Rome "Tor Vergata", Rome, Italy, 2Dipartimento di Studi 
Farmaceutici, University of Rome "La Sapienza", Rome, Italy, 3Department of Haematology, University of Rome "Tor Vergata", Rome, Italy, 
4Department of Biology, University of Rome "Tor Vergata", Rome, Italy, 5Research Center Ospedale Bambino Gesù, Rome, Italy, 6Department of 
Experimental Medicine, University of Rome "La Sapienza", Rome, Italy and 7IRCCS San Raffaele Pisana, Rome, Italy
Email: Gabriella Marfe* - gmarfe1@virgilio.it; Carla Di Stefano - carladistefano@virgilio.it; Romano Silvestri - romano.silvestri@uniroma1.it; 
Elisabetta Abruzzese - abruzzes@uniroma2.it; Gianfranco Catalano - gianfranco.catalano@uniroma2.it; Livia Di 
Renzo - livia.direnzo@uniroma1.it; Giuseppe Filomeni - filomeni@bio.uniroma2.it; Ezio Giorda - eziogiorda@hotmail.com; Giuseppe La 
Regina - giuseppelaregina@uniroma1.it; Emanuela Morgante - emorgante@yahoo.com; Maria Rosa Ciriolo - ciriolo@bio.uniroma2.it; 
Matteo Antonio Russo - matteoantonio.russo@uniroma1.it; Sergio Amadori - sergio.amadori@ptvonline.it; Paola Sinibaldi-
Salimei - paola.sinibaldi@uniroma2.it
* Corresponding author    
Abstract
Background: The objective of this study was to gain insight into the molecular mechanism of
induced cell death (apoptosis) by PYRROLO [1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs)
series compounds, using human (K562) cells as a model.
Methods: We focused our attention on some members of the PBTDs family to test their potential
apoptotic activity in K562 cells. Important apoptotic activity was demonstrated, as evidenced by
the concentration and percentage of cell death quantified by measuring PI-uptake by flow
cytometry, and DNA fragmentation analyzed by agarose gel electrophoresis, generating a
characteristic ladder pattern of discontinuous DNA fragments. The expression of Bcl-2 family was
tested using western blotting and transfection method.
Results:  PBTDs-mediated suppression of K562 cell proliferation was induced by apoptosis
characterized by the appearance of DNA fragmentation and was associated with the poly(ADP-
ribose)polymerase (PARP) cleavage. PBTD-1 and -3 treatment resulted in caspase-3 activation
through down-regulation of Bcl-2 and up-regulation of Bax. Furthermore, we used K562/vector and
K562/bcl-2 cells, which were generated by transfection of the cDNA of the Bcl-2 gene. As compared
with K562/vector, K562/Bcl-2 cells exhibited a 4-fold greater expression of Bcl-2. Treatment with
10  μM PBTD-1 and -3 for 24 h produced morphological features of apoptosis and DNA
fragmentation in K562/vector cells, respectively. In contrast, PBTD-1 and -3-induced caspase-3
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activation and apoptosis were inhibited in K562/Bcl-2. Furthermore, Bcl-2 overexpressing cells
exhibited less cytocrome c release during PBTDs-induced apoptosis.
Conclusion: These results indicate that PBTDs effectively induce apoptosis of K562 leukemia cells
through the activation of caspase cascades. In addition, these findings indicate that Bcl-2 inhibits
PBTD-1 and -3 induced-apoptosis via a mechanism that interferes with cytocrome c release, and
the activity of caspase-3, which is involved in the execution of apoptosis.
Background
The understanding of signals and pathways that regulate
cell proliferation and apoptosis is crucial in searching
devices capable diseases such as cancer. In fact, a raised
threshold for apoptosis represents a central step in tumor-
igenesis, and tumors that possess alterations of the cell
death signalling system are often resistant to chemiother-
apy [1,2]. The evasion of apoptosis in response to death
signals is achieved by malignant cell using set of muta-
tions that inactive pro-apoptotic proteins or up-regulate
anti-apoptotic protein [3].
Chronic myeloid leukaemia is an hematopoietic stem cell
cancer cytologically characterized by the Philadelphia
chromosome, which results from reciprocal translocation
between chromosome 9 and chromosome 22 [4,5]. This
mutation leads to the formation of the chimeric fusion
protein Bcr/Abl, which manifests an uncontrolled tyro-
sine kinase activity. The expression of Bcr-Abl also con-
tributes to confer apoptosis resistence after growth factors
withdrawal or DNA damage. The ability to escape the nor-
mal death program provides a huge proliferative advan-
tage and represents, especially during the accelerated or
blast phase of disease, an obstacle to the successful treat-
ment of this pathology, even when employing the new
chemotherapic agent Imatinib [6-9]. In fact, Bcr-Abl
kinase stimulates a variety of downstream survival path-
ways, including the mitogen-activated protein kinase cas-
cade, Akt, the signal transducers and activators of
transcription. Activation of these pathways in Bcr-Abl pos-
itive cells results in increased expression of several anti-
apoptotic proteins, such Bcl-xl and Bcl-2, which block the
release of cytocrome c from mithocondria, resulting in
inactivation of caspases [10,11].
Two important groups of proteins involved in apoptotic
cell death are the members of the Bcl-2 family [12] and a
class of cysteine proteases known as caspases [13]. The
Bcl-2 family can be classified into two functionally dis-
tinct groups: antiapoptotic proteins and pro-apoptotic
proteins. Bcl-2, an antiapoptotic protein, is known for reg-
ulating apoptotic pathways and protecting against cell
death. Bax, a pro-apoptotic protein of that family, is
expressed abundantly and selectively during apoptosis
and promotes cell death. Increasing the ratio of Bcl-2 to
Bax has commonly been used to determine the induction
of apoptosis in several tissues [14]. The caspases are
aspartate-specific cysteine proteases that have emerged as
the central executioner of apoptosis. Primary mechanism
of apoptosis [13,15] goes through caspase-3 activation,
which can be activated through cytosolic release of cyto-
chrome c by Bax protein [16].
In the present study, we show that PBTDs suppresses pro-
liferation of K562 cancer cells by causing apoptosis
together with induction of proapoptotic Bcl-2 family
members Bax and down-regulation of antiapoptotic pro-
teins Bcl-2 and Bcl-xL, therefore leading to activation of
caspases. In addition, overexpression of Bcl-2 inhibits
PBTD-1 and -3 induced-apoptosis, which prevents the
accumulation of cytocrome c in the cytosol, thereby pre-
serving the caspase-3 in the inactive zymogen state and
blocking molecular cascade of apoptosis.
Methods
Chemistry
Pyrrolo [1,2-b][1,2,5]benzothiadiazepines 5,5-dioxide
(PBTDs) were developed in search for novel non-nucleo-
side anti-AIDS agents because they were discovered as
potent inhibitors of the HIV-1 reverse transcriptase of HIV-
1 [17]. In 2001 some pyrrolo[1,5]benzoxazepines were
reported to induce apoptosis in CML cells by bypassing the
apoptotic suppressor activity of the Bcr-Abl protein [16].
Taking into account these findings we selected some PBTD
derivatives (compounds 1–3) having structural elements
we thought crucial for the modulation of the apoptotic
activity: (i) a benzofused heterocyclic ring; (ii) a sulfone
group; (iii) a short side chain bearing COOH or COOR
functions; (iv) an aroyl group at position 10 (Figure 1).
Cells and Culture Conditions
The list and biological characteristics of long-tern cultured
leukaemia cells that have been previously described and
used in the present study, is illustrated in Table 1[18].
Cell lines were grown in suspension in RPMI 1640
medium supplemented with 10% (v/v) heated-inacti-
vated fetal bovine serum (FbS) 100 U ml-1 of penicillin
and 100 μg of streptomycin ml-1. For treatment with com-
pounds 1, 3, exponential growing the different cells lines
were collected and resuspended in fresh culture medium.
Resistant clones (IM-R-K562) are a gift from CarloBMC Cancer 2007, 7:207 http://www.biomedcentral.com/1471-2407/7/207
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Gambacorti-Passerini (National Cancer Institute, Milan,
Italy) [19] and have been established by continuous expo-
sure to imatinib as described [18]. No Bcr-Abl amplifica-
tion nor Bcr-Abl point-mutations have been detected in
this cell line (data not shown).
In the first series of experiments, K562 cells, were added in
25-cm culture flasks and incubated with different concen-
trations of in the range of 5, 10, and 15 μM for 24 hrs at
37°C. Briefly, then the cells maintained in RPMI 1640
medium supplemented for 3 hrs at 37°C. Furthermore,
K562, HL60, Jurkatt, U937 and IM-R-K562 cells were
treated PBTD-1 and-3 were incubated at the concentration
10 μM for 8, 16 and 24 hrs.
K562 cells stably transfected with an eukaryotic expres-
sion vector CMV/Bcl-2 (K562/Bcl-2) or control CMV/
vector (K562/vector) vector.
Assessment of cell viability
After exposure to PBTD-1 and -3, cell viability was assessed
by propidium iodide (PI) exclusion. Cells (0.5 × 106) were
re-suspended in PBS and 50 μg/ml PI prior to flow cyto-
metric analysis (FACScan; Becton Dickinson, Oxford, UK).
DNA fragmentation assay
Briefly, cells were washed twice with phosphate-buffered
saline (PBS) and lysed by addition of a hypotonic solution
(1% NP-40 in 20 mM EDTA, 50 mM Tris-HCl pH 7.5).
After centrifugation at 1600 × g for 5 min, the supernatant
was collected and the extraction was repeated with the
same lysis buffer. The supernatants was brought to 1% SDS
and treated with RNase A (final concentration 5 mg/ml)
for 2 h at 56°C followed by digestion with proteinase K
(final concentration 2.5 mg/ml) at 45°C for at least 6 h.
Before hydrolysis, a further cleaning of DNA was per-
formed by phenol-chloroform extraction, followed by
three successive ethanol precipitation in 2 M ammonium
acetate. Pellets were dried for 30 min and resuspended in
200 μl Tris-EDTA pH 8.0 [20]. Aliquots of 20 μl containing
10 μg DNA were electrophoresed in 1.5% agarose gel.
Protein extraction and Western blot analysis
Cells were homogenized directly into lysis buffer (50 mM
HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10%
glycerol, 1% Triton X-100, 1 mM phenylmethylsulfonyl
fluoride, 1 μg/ml aprotinin, 0.5 mM sodium orthovanad-
ate, and 20 mM sodium pyrophosphate). The lysates were
clarified by centrifugation at 14,000 × 10 min. Protein
concentrations were estimated by an assay (Bio-Rad) and
boiled in Laemmli buffer (0.125 M Tris-HCl (pH 6.8),
Molecular structures of PBTDs Figure 1
Molecular structures of PBTDs.
Table 1: Origin and biological characteristics of long-term cultured haematopoietic malignant cell lines used
No. Line Origin
1 K562 CML patient in blast crisis
2 HL- 60/M- Promyelocitic human leukemia
3 U937 Promyelocitic human leukemia
4 Jurkat acute T cell leukemia
5 IM-resistant K562 IM-resistant CML patient in blast crisis*
Resistant clones (IM-R-K562) are a gift from Carlo Gambacorti-Passerini (National Cancer Institute, Milan, Italy) (Morotti et al., 2006).BMC Cancer 2007, 7:207 http://www.biomedcentral.com/1471-2407/7/207
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4% SDS, 20% glycerol, 10% 2-mercaptoethanol,
and 0.002% bromophenol blue) for 5 min before
electrophoresis. Proteins were subjected to SDS-PAGE
(12.5% polyacrylamide). After electrophoresis, proteins
were transferred to nitrocellulose membranes (Immo-
bilon, Millipore Corp., Bedford, MA); complete transfer
was assessed using pre-stained protein standards (Bio-
Rad, Hercules, CA). After blocking with Tris-buffered
saline-BSA (25 mM Tris (pH7.4), 200 mM NaCl, and
5% BSA), the membrane was incubated with the primary
antibodies. The following first antibodies, dissolved in
5% bovine serum albumin-TBST, were used: anti-Bax
MAb (dilution 1:250) anti-BclXL MAb (dilution 1:250),
anti-Bcl2 MAb (dilution 1:2,000), anti-poly(ADP-ribose)
polymerase (PARP) (dilution 1:2000), anti-caspase-3
MAb (dilution 1:1,000) (all antibodies from Santa Cruz
Biotechnology) and anti-β-actin MAb (dilution 1:7,500;
Sigma). Membranes were then incubated with the horse-
radish peroxidase-conjugated secondary antibody
(1:10,000) (at room temperature), and the reaction was
detected with an enhanced chemiluminescence system
(Amersham Life Science, Buckinghamshire, UK).
Cytosolic protein extraction and cytochrome c 
immunoblot
Cytochrome c immunoblot was carried out using a mod-
ified protocol of Kluck et al. [21]. Cultured cells were
treated with PBTD-1 and -3 in RPMI 1640 medium and
then collected with lysis buffer (1 mM CaCl2, 1 mM
MgCl2, 1% NP-40, 1 μg/ml leupeptin, 1 μg/ml aprotinin,
1 μM PMSF, and 100 μM NaVO4). After the lysis mixtures
were incubated on ice for 20 mins, they were centrifuged
at 14,000 rpm for 15 min. The supernatants were col-
lected and total cytosolic proteins were quantitated by a
Bradford spectrometer. About 80 μg protein was loaded in
a 10% SDS-PAGE gel and transferred to polyvinylidene
difluoride (PVDF) membrane at a constant current of
250 mA for 2 hours. The membrane was incubated with
the primary cytochrome c polyclonal antibody (H-104,
Santa Cruz) overnight at a dilution of 1:500. Horseradish
peroxidaseconjugated anti-rabbit secondary antibody at a
1:1000 dilution was incubated with the membrane for
another 1 hour at room temperature. The protein was
detected with enhanced chemiluminescence for
autoradiography
Light and electron microscopy
The cells were fixed in 2.5% glutaraldhyde in 0.1 M PBS
pH 7.3 and stored at 4 C. For processing the specimens
were post-fixed for 1 h in 1.33% osmium tetroxide in
0.1 M PBS. Dehydratation and resin embedding were per-
formed following a standard schedule. Semi-thin sections,
0.3 nm thick were cut, stained with Azur II and observed
under a Nikon optical microscope. Ultra-thin sections,
70 nm thick were cut mounted on copper grid, stained
with uranyl acetate and lead hydroxide and examined
under a Philips CM-10 trasmission electron microscope at
an accelerating voltage of 60 kV.
Morphometry
The number of apoptotic cells was determined in 10 dig-
ital micrographs at magnification of 20. A total of 500
cells for each condition were studied. A Nikon Eclipse
1000 digital microscope equipped of Eclipse Net software
has been used.
Results
PBTD-1 and -3 induced Apoptosis in cancer cells
To gain insights into the mechanism of PTBD-1 and -3
suppression of K562 cell proliferation, we determined its
apoptotic effect by flow cytometry following staining with
propidium iodide (Table 2, 3). Apoptosis induction by
PBTD-1 and 3 was confirmed by analysis of DNA
fragmentation and the results are shown in Figure 2A, 2B,
Table 2: Percentage of the cell death was quantified measuring PI-uptake by flow cytometry. PBTD-3 10 μM.
Time hours K562 % apop.
IM-Resistant K562 % 
apop U937 % apop. HL60 % apop Jurkatt % apop
8 4 64 44 04 24 1
16 65 63 67 70 71
24 66 64 72 73 73
Table 3: Percentage of the cell death was quantified measuring PI-uptake by flow cytometry. PBTD-1 10 μM.
Time hours K562 % apop.
IM-Resistant K562 % 
apop U937 % apop. HL60 % apop Jurkatt % apop
8 3 43 23 83 93 9
16 60 59 65 66 67
24 64 63 66 68 69BMC Cancer 2007, 7:207 http://www.biomedcentral.com/1471-2407/7/207
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2C, 2D. The other cell lines were included in the analysis
for direct comparison. Treatment of K562 cells with
PBTDs resulted in a time-dependent manner and statisti-
cally significant increase of DNA fragmentation, com-
pared to controls (figure 2). The effects of these agents
were also examined in an imatinib mesylate-resistant
CML cell line (IM-K562-R). Consistent with the results of
cell survival assays, PTDBs treatment is able to cause DNA
fragmentation in these cells (Figure 2D). All together,
these results indicated that PBTDs-mediated inhibition of
K562 cell proliferation was due to apoptosis induction.
Preliminary structure activity relationships (SARs)
highlighted the crucial role of the ethoxycarbonyl fuction.
Time-dependent DNA fragmentation Figure 2
Time-dependent DNA fragmentation. Cells were exposed to the indicated concentrations of synthetic compounds. Cells were 
harvested by centrifugation and DNA was extracted. The DNA fragments were separated on 1,8% agarose gel electrophoresis 
and visualized under ultraviolet. Cells were exposed to 10 μM PBTD-1 and PBTD-3 for 8,16, and 24 h.BMC Cancer 2007, 7:207 http://www.biomedcentral.com/1471-2407/7/207
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In fact, independently from the 4-methylbenzoyl group at
position 10 of the pyrrole [1,2-b][1,2,5]benzothiadi-
azepine ring, compounds 1 and 2 having an ethoxycarbo-
nyl chain at position 11 were able to induce apoptosis. On
the contrary, hydrolysis of the ester 1 to acid 2 led to a
product deprived of apoptotic activity. Speculation about
these findings suggests that arguably the acid 2 is less able
to cross the cell membrane than the esters 1 and 3 one. In
designing novel PBTDs as apotosis inductors it will be
important to take in consideration the hydrophobic/
hydrophilic balance as well as the ionic character of the
molecule.
Effect of PBTD-1 and -3 treatment on levels of Bcl-2 
Family Proteins
We examined whether PBTDs induce cell death by modu-
lating the expression of Bcl-2 family members, which ulti-
mately determine the cell's response to apoptotic stimuli.
The PBTD-1 and 3 treatment caused a rapid increase in the
level of Bax protein. The PBTDs-mediated induction of
Bax protein expression was evident as early as 8 hours
after treatment and persisted along the experiment
(24 hours after treatment).
The levels of antiapoptotic proteins Bcl-xL and Bcl-2 were
initially increased after treatment with PBTDs (8 hours)
but declined at 16- and 24-hour time points (Figure 3).
Such results suggested that PBTDs-induced cell death
might be regulated by Bcl-2 family proteins.
Expression levels of bcl-2 overexpressed cells
In order to evaluate the functional role played by bcl-2 in
preventing apoptosis induced by PBTDs, we first stably
transfected K562 cells with a plasmid constitutively
producing high levels of Bcl-2. Western Blot analysis
revealed that K562/Bcl-2 cells exhibited a ~4-fold in bcl-2
expression compared with cell containg empty-vector
(Figure 4A). In contrast, level of bax was equivalent in
K562/Bcl-2 and K562/vector cells (Figure 4A).
Immunoblotting for Bax, Bcl-xL, and Bcl-2 using lysates from  K562 cells treated with 10 μM PBTD-1 and PBTD-3 for the  indicated time periods Figure 3
Immunoblotting for Bax, Bcl-xL, and Bcl-2 using lysates from 
K562 cells treated with 10 μM PBTD-1 and PBTD-3 for the 
indicated time periods. The blots were stripped and rep-
robed with anti-actin antibody to normalize for differences in 
protein loading. Immunoblotting for each protein was done 
at least twice using independently prepared lysates, and the 
results were comparable.
A) Overexpression of Bcl-2 in K562 cells Figure 4
A) Overexpression of Bcl-2 in K562 cells. Immunoblot analy-
sis of cell lysate from control (K562/vector) or Bcl-2 trans-
fected (K562/Bcl-2). The blot was probed with anti-Bcl-2 and 
anti-Bax. B) Fragmentation of genomic DNA in cells after 
treatment for 24 h with PBTD-1 and -3.BMC Cancer 2007, 7:207 http://www.biomedcentral.com/1471-2407/7/207
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Bcl-2 significantly prevents apoptosis induced by PBTDs
An important hallmark of apoptosis is the degradation of
chromosomal DNA at internucleosomal linkages. We
analyzed DNA fragmentation induced by in K562/Bcl-2
and K563/vector cells. Following agarose gel electro-
phoresis of K562/vector cells treated with 10 μM PBTDs
for 24 h, a typical ladder pattern of internucleosomal frag-
mentation was observed (Figure 4B). In contrast, DNA
fragmentation in K562/Bcl-2 was inhibited (Figure 4B).
Involvement of Caspase-3 in PBTD-1 and -3-Induced 
Apoptosis
Our previous study demonstrated that the exposure to
PBTDs for 24 h induces the activation of caspase-9 and 8
[22,23]. To determinate whether PBTDs-induced apopto-
sis was associated with the activation of caspase-3, we per-
formed an immunoblotting that revealed cleavage of
procaspase-3 after treatment with PBTD-1 and -3 for 8 to
24 hours (Figure 5A). In order to confirm the activation
and execution of apoptosis by caspase-3, the cleavage of
PARP (which is well accepted as one of the target proteins
for caspase-3) was studied. As shown in Figure 5B, a PARP
cleavage band was observed concomitantly with the
occurrence of caspase-3 cleavage.
Furthermore, we determined the activity of caspase-3 in
K562/bcl-2 and K562/vector cells. Caspase-3 is activared
by proteolytic processing of the 32 KDa form into two
smaller subunits. Activity of caspase-3 during PTBDs-
induced apoptosis was measured by a decrease in pro-
enzyme level using western blot analysis. As shown in
Figure 5C, treatment resulted in a decrease in the level of
caspase-3 in K562 cell control and K562/vector cells
exposed 10 μM PTBDs for 24 h. In contrast, the levels of
caspase-3 not significantly altered in PBTDs-treated K562/
Bcl-2 (Figure 5C).
A. Immunoblotting for caspase-3 (full-length and cleaved intermediate) using lysates from K562 cells treated with 10 μM PBTD- 1 and PBTD-3 for the indicated time periods Figure 5
A. Immunoblotting for caspase-3 (full-length and cleaved intermediate) using lysates from K562 cells treated with 10 μM PBTD-1 
and PBTD-3 for the indicated time periods. The blots were stripped and reprobed with anti-actin antibody to ensure equal 
protein loading. Immunoblotting for each protein was done at least twice using independently prepared lysates, and the results 
were comparable. B. PARP cleavage was also analyzed by immunoblotting under the same condition Data indicate 116 kDa PARP 
(upper bands) and 85 kDa apoptosis-related cleavage fragment (lower bands). C. K562/vector and K562/Bcl-2 cells were treated 
with PBTDs. Equal amounts of cell lysates were subjected to electrophoresis by western blot for caspase-3.BMC Cancer 2007, 7:207 http://www.biomedcentral.com/1471-2407/7/207
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PBTDs induce cytochrome c release in K562 cells
There is accumulating evidence that the mitochondria
play an essential role in many forms of apoptosis by
releasing apoptogenic factors, such as cytochrome c and
apoptosis-inducing factor (AIF). Cytocrome c directly
actives caspases by binding to Apaf-1 in presence of ATP
[14]. To examine the release of cytocrome c in PBTDs-
treated K562 cells K562/vector and K562/B, we conducted
western blotting analysis. Importantly, the overexpression
of anti-apoptotic Bcl-2 in k562 cells significantly blocked
PBTDs-induced release of cytochrome c from mitochon-
dria (Figure. 6A, 6B).
Morphology
The light microscope analysis of semi-thin sections pro-
vided clear evidence of apoptosis in the K562 cells treated
with PBTD-1 and -3. Figure 7 showed typical morpholog-
ical apoptotic features consisting in: cytoplasmic
vacuolization, patterns of chromatin condensation and
micronuclei in K562 cells incubated with PBTD-3
compound.
Discussion
Increasing understanding of molecular bases of cancer has
undoubtedly demonstrated that it is the inappropriate
expression and activity of particular protein involved in
intercellular and intracellular signalling networks that
causes radical changes in cell behaviour, enabling pro-
longed cell survival and unlimited proliferative capacity.
Chronic myeloid leukaemia is paradigm of how an
uncontrolled and perpetually switched on tyrosine kinase,
like the fusion-protein Bcr-Abl, could turn normal cells
into malignant ones [9]. Thus, considerable effort have
been made for understanding the molecular mechanism
underlying the transforming Bcr-Abl activity to possibly
develop new therapeutic approaches, although several
aspect are still obscure [6-11]. These considerations
constituted the preamble of our study, which was at eval-
uating the possibility that PBTDs induce apoptosis in
K562 cells.
PBTDs-induced apoptosis is mediated by caspase-3 activa-
tion, downregulation of Bcl-2 and Bcl-xL proteins and
upregulation Bax protein. Furthermore, Bcl-2 overexpres-
sion blocks PBTDs-induced apoptosis in K562 cells by
inhibition of caspase-3 activity.
Since the discovery of Bcl-2 as anti-apoptotic protein,
several theories the Bcl-2 anti-apoptotic mechanism have
been proposed [21,24,25]. The Bcl-2 anti-apoptotic func-
tion may explained by its ability to control several key
steps of apoptosis signalling. Bcl-2 can form ion chan-
nels in biological membranes [26,27]. The ion channel
activity of Bcl-2 may control apoptosis by influencing the
permability of intracellular membranes and cytochrome
c release from mitocondria [26,27]. The release of
cytocrome c induces the activation of caspase-3 and
DNA fragmentation. Our data showed that the release
of cytochrome c from mithocondria in K562 cells
preceded caspase activation by PBTDs. However, overex-
pression of Bcl-2 protein may rescue cells from apopto-
sis, blocking the release of cytocrome c from mitocondria
and caspase-3 activation.
A. Cytochrome c release occurs between 8 and 24 after treatment Figure 6
A. Cytochrome c release occurs between 8 and 24 after treatment. K562 cells were treated with both compounds and col-
lected at each time point. The cytosolic and mitochondria-enriched fractions were prepared and western blot analyses were 
performed as described in Methods. B. K562/vector and K562/Bcl-2 were treated with PBTDs. The cytosolic and mitochon-
dria-enriched fractions were prepared and western blot analyses were performed as described in Methods.BMC Cancer 2007, 7:207 http://www.biomedcentral.com/1471-2407/7/207
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Thus, it seems that Bcl-2 family members play an impor-
tant role in execution of PBDTs-induced cell death. Our
findings suggest that these proteins are involved in the
intracellular pathway leading to apoptotic death induced
by these compounds. Taken together, the data indicate
that the down-regulation of Bcl-2 and Bcl-xL and the
upregulation of Bax could be responsible for PBTDs-
induced apoptosis in K562 cells.
In summary, our studies demonstrate that PBTDs treat-
ment of K562 cells induces cytochrome c release which
activates pro-caspase-3 and DNA fragmentation. Moreo-
ver, expression of Bcl-2 inhibits PBTDs-induced apoptosis
and prevents the release of cythocrome c from the mithoc-
ondria. Conventional cancer chemotherapeutic drugs
indirectly induce cancer cell apoptosis, but more effective
outcomes should be reached by direct activation of the
apoptotic machinery. Accordingly, approaches of antican-
cer agents that cause down-regulation of antiapoptotic
Bcl-2 family of proteins and/or up-regulation of proapop-
totic Bcl-2 family of proteins should be carried out
Conclusion
In view of accumulating evidence that PBTDs may be an
important determinant of clinical response in leukaemia,
further efforts to explore this therapeutic strategy appear
warranted.
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A.-Most frequent nuclear apoptotic changes include: classical nuclear body formation with clumped chromatin and nuclear frag- mentation Figure 7
A.-Most frequent nuclear apoptotic changes include: classical nuclear body formation with clumped chromatin and nuclear frag-
mentation. (× 9800); the bar represents 1 μm. (K562 treated with PBTD-3). B.-An other less frequent nuclear change is dis-
played in this picture: chromatin clumping and membrane complex fragmentation, likely due to the degradation of laminin fibers 
of nuclear dense lamina by caspase-3. Note the close association between nuclear membranes (paired cysternae) and clumped 
chromatin. (× 2000); the bar represents 3 μm.(K562 treated with PBTD-3). C.-A detail of the insert is shown. (× 9800); the bar 
represents 0,5 μm.BMC Cancer 2007, 7:207 http://www.biomedcentral.com/1471-2407/7/207
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